Le Lézard
Classified in: Health
Subject: ATY

InMode Ltd. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 15, 2024 to Discuss Your Rights - INMD


NEW YORK, March 22, 2024 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of InMode Ltd..

Shareholders who purchased shares of INMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/inmode-loss-submission-form/?id=72076&from=4

CLASS PERIOD: June 4, 2021 to October 12, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) InMode heavily discounts almost every device it sells; (ii) demand for InMode's products was driven by InMode's willingness to discount its products; (iii) InMode violated U.S. Food and Drug Administration ("FDA") regulations by engaging in off-label marketing and promoting products for treatment of indications for which they lack FDA approval; and (iv) InMode violated FDA regulations by failing to timely report injuries caused by its devices.

DEADLINE: April 15, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/inmode-loss-submission-form/?id=72076&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of INMD during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 15, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 09:20
Inflammasome Therapeutics (https://www.inflam.com), a private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a...

at 09:17
NanoAi Technologies, a company pioneering advancements in threat detection, today unveiled the NanoAi Technologies analyzer, a groundbreaking device designed to revolutionize security and safety measures across various sectors. This lightweight and...

at 09:15
The "Infectious Diseases Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access...

at 09:05
GE HealthCare today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Portrait VSM vital signs monitor that can provide clinicians with an accurate view of patient vital signs to support...

at 09:05
Merck , known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company's investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European...

at 09:00
? 2023 marked by Ceapro's achievement of key milestones and progress toward its next phase of growth ? R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the...



News published on and distributed by: